UOC
KALA icon

UBS O'Connor’s KALA BIO KALA Stock Holding History

UBS O'Connor’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,771
Closed -$660K – 378
2025
Q2 		$660K Sell
2,771
-647
-19% -$126K 0.02% 258
2025
Q1 		$979K Sell
3,418
-161
-4% -$60.9K 0.02% 189
2024
Q4 		$1.24M Buy
3,579
+326
+10% +$103K 0.03% 210
2024
Q3 		$927K Buy
3,253
+302
+10% +$95.3K 0.02% 289
2024
Q2 		$1.05M Buy
2,951
+1,500
+103% +$496K 0.03% 288
2024
Q1 		$569K Buy
+1,451
New +$539K 0.02% 325

Other funds holding KALA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

UBS O'Connor's KALA Position: Q3 2025 in Review

UBS O'Connor sold out of KALA BIO (KALA) in Q3 2025, closing a stake of 2,771 shares — an estimated $660K sold.

UBS O'Connor first reported a position in KALA in Q1 2024 and held it in 6 quarters. The position peaked at $1.24M in Q4 2024. 22 funds tracked by Wall St. Rank hold KALA as of Q3 2025.

  • UBS O'Connor reported no remaining KALA BIO position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 2,771 KALA BIO shares in Q3 2025, an estimated $660K.
  • UBS O'Connor first reported a position in KALA BIO in Q1 2024 and held it in 6 quarters.
  • UBS O'Connor's KALA BIO position peaked at $1.24M in Q4 2024.
  • 22 funds tracked by Wall St. Rank held KALA BIO as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.